Abstract: IL-17 inhibitors of secukinumab, ixekizumab and brodalumab, approved by FDA in the treatment of psoriasis, have clinically been demonstrated to be more effective, tolerable and safe, compared to TNF-αinhibitors. Three IL-23 inhibitors including risankizumab，guselkumab and tildrakizumab are currently under phase III clinical trials. The primary results of the clinical trials showed the advantage of faster skin improvement, higher skin clearance and fewer injections than TNF-αinhibitors. The update of these six new biological agents in the treatment of psoriasis is reviewed in this article.

Key words: psoriasis, interleukin 17 and 23, secukinumab, ixekizumab, brodalumab, risankizumab, guselkumab, tildrakizumab